Search
+
    SEARCHED FOR:

    MEDICINES PATENT POOL

    Cancer care can be cheaper: 6 steps to cut drug costs

    India has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care, quality checks, cost-effective medicines and pooled procurement to improve affordability.

    The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reach

    For millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that remain out of reach, the affordability crisis runs deep. A proposed cap may help, but question remains if it will be enough to change the picture.

    In 1846, Elias Howe patented a lockstitch sewing machine; the patent war around it helped create a licensing model still used in 5G

    Elias Howe's journey in the invention of the sewing machine was marked by challenges, as he faced fierce opposition from tailors and struggled with funding. Traveling to England in search of financial support led to a contentious legal battle over his creation. Ultimately, Howe triumphed in court, asserting his rights to the design, a conflict that birthed America's first patent pool, a foundational model that shapes technology licensing paradigms today.

    AbbVie loses patent plea for Hep C drug

    The Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to affordable treatment for millions. The patent office refused the application after AbbVie failed to contest oppositions and chose to abandon it. This refusal prevents AbbVie from extending its patent monopoly by five years.

    Aurobindo to produce, supply long acting HIV treatment drug

    Aurobindo Pharma will manufacture and supply long-acting injectable HIV treatment, cabotegravir, across 133 countries through a voluntary licensing agreement. This agreement with Medicines Patent Pool and ViiV Healthcare expands access to an alternative to daily pills, offering injections every one or two months. The move aims to make the advanced treatment widely available and affordable in low and middle-income countries.

    Aurobindo Pharma shares rise 3% after subsidiary signs license for generic version of Nilotinib Capsules

    Shares of Aurobindo Pharma went up by 3% after the company announced that its subsidiary Eugia Pharma has signed a voluntary license with Medicines Patent Pool to create and market a generic version of Nilotinib Capsules. Aurobindo Pharma’s wholly-owned subsidiary Eugia Pharma Specialities has entered a voluntary sublicensing agreement with Medicines Patent Pool to manufacture and market the drug in 44 low and middle-income countries for the treatment of chronic myeloid leukemia.

    The Economic Times
    BACK TO TOP